Inhibition of lymphocyte activation by ouabain. Interference with the early activation of membrane phospholipid metabolism.
Activation of lymphocytes by antigens and mitogens can effectively be prevented by ouabain, a known inhibitor of (Na+ + K+)-ATPase. Recently it was shown that lowering of intracellular levels of monovalent cations is not involved in the inhibitory effect of ouabain. (Na+ + K+)-ATPase was found to be closely associated with acyl-CoA : lysophosphatidylcholine acyltransferase in the plasma membrane of lymphocytes. Both enzymes are activated as an immediate consequence of mitogen binding. Human peripheral lymphocytes were stimulated with concanavalin A. Ouabain suppressed the induction of RNA and DNA synthesis in a concentration-dependent way. Increase of RNA synthesis was suppressed only if the glycoside were added within the first hours of activation. If ouabain was added later, incorporation of uridine remained at the rate that was reached at the time of glycoside administration, pointing to an early event where ouabain may be operative. Ouabain, in a dose-dependent manner similar to that affecting RNA and DNA synthesis, inhibited the increase in the incorporation of oleate into phospholipids in stimulated lymphocytes, whereas the turnover of phospholipid fatty acids in resting lymphocytes was unaffected. Increasing extracellular K+ concentrations reversed the binding of ouabain to lymphocytes. Simultaneously, the inhibition of stimulated RNA synthesis was decreased and the inhibition of oleate incorporation was reversed. These results suggest that the suppression of lymphocyte activation by ouabain is due to the inhibition of membrane phospholipid metabolism mediated by (Na+ + K+)-ATPase.
D008243:1-Acylglycerophosphocholine O-Acyltransferase / Q000378:metabolism; D002462:Cell Membrane / Q000378:metabolism*; D003208:Concanavalin A / Q000494:pharmacology; D004247:DNA / Q000096:biosynthesis; D004305:Dose-Response Relationship, Drug; D006801:Humans; D008213:Lymphocyte Activation / Q000187:drug effects*; D019301:Oleic Acid; D009829:Oleic Acids / Q000378:metabolism; D010042:Ouabain / Q000494:pharmacology*; D010743:Phospholipids / Q000378:metabolism*; D012313:RNA / Q000096:biosynthesis; D000254:Sodium-Potassium-Exchanging ATPase / Q000378:metabolism
D009829:Oleic Acids; D010743:Phospholipids; D003208:Concanavalin A; D019301:Oleic Acid; D010042:Ouabain; D012313:RNA; D004247:DNA; D008243:1-Acylglycerophosphocholine O-Acyltransferase; D000254:Sodium-Potassium-Exchanging ATPase